Skip to content

EBIT at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$53.42M-148%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$24.22M+10.7%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$40.82M+1.9%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$43.49M-103%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$19.67M-187%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$1.3M+50.8%
Operating income-$13.1M+0.2%
Net income-$18.3M-47.4%
EPS (diluted)-$0.32+48.4%

Balance sheet

See full
Cash & equivalents$100.8M+97.9%
Total debt$2.1M-73.2%
Total equity$30.9M-40.1%
Total assets$105.5M+68.0%

Cash flow

See full
Operating cash flow-$11.0M+23.1%
CapEx--100%
Free cash flow-$11.0M+24.6%

Valuation

See full
Market cap$226.92M+666%
Enterprise value$128.2M-3,860%
P/S57.7×+47.8×

Profitability

See full
Operating margin-1,335.2%-512pp
Net margin-2,193.7%-581pp
FCF margin-1,254%

Returns & leverage

See full
Return on equity-209.3%
Debt / equity0.1×-0.1×
Current ratio6.1×-1.9×

Where this comes from

Calculated from CalAmp’s reported figures.

The official record: CalAmp’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CalAmp's EBIT?
CalAmp (CAMP) reported EBIT of -$13.07M in Q1 2026.
How has CalAmp's EBIT changed year-over-year?
CalAmp's EBIT increased by 0.2% year-over-year, from -$13.1M to -$13.07M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.